| Non-Hodgkin Lymphoma (NHL) |
0 |
0.9 |
| Remission |
0 |
0.62 |
| B-Cell Lymphoma |
0 |
1 |
| Diffuse Large Cell Lymphoma |
0 |
0.49 |
| Biologic Therapy |
0 |
0.46 |
| Lymphoma |
0 |
0.41 |
| Toxicology |
0 |
0.4 |
| Neutropenia |
0 |
0.31 |
| Refractory |
0 |
0.31 |
| CAR-T |
0 |
0.28 |
| COVID-19 |
0 |
0.24 |
| Intravenous |
0 |
0.2 |
| T-Lymphocyte |
0 |
0.2 |
| Healthcare and Medical Technology |
0 |
0.15 |
| Aminotransferase |
0 |
0.1 |
| Anthracyclines |
0 |
0.1 |
| Antigens |
0 |
0.1 |
| Canada |
0 |
0.1 |
| Cancer |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Corticosteroids |
0 |
0.1 |
| Cytokines |
0 |
0.1 |
| Neurotoxicity |
0 |
0.1 |
| Orbit |
0 |
0.1 |
| Prognosis |
0 |
0.1 |
| Receptors |
0 |
0.1 |